Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 10 000 UNITS AND DEXTROSE 5 IN PLASTIC CONTAINER versus PRADAXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 10 000 UNITS AND DEXTROSE 5 IN PLASTIC CONTAINER versus PRADAXA.
HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER vs PRADAXA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, accelerating its inhibition of thrombin (factor IIa) and factor Xa, thereby preventing thrombus formation and propagation.
Direct thrombin inhibitor; binds reversibly to the active site of thrombin, preventing fibrinogen cleavage and subsequent thrombus formation.
IV: Initial bolus of 5000 units followed by continuous infusion at 1300 units/hour, adjusted based on aPTT. Typical infusion range 1000-2000 units/hour.
150 mg orally twice daily; for patients with CrCl 15-30 mL/min, 75 mg orally twice daily.
None Documented
None Documented
30-60 minutes at therapeutic doses, dose-dependent (e.g., 100 U/kg yields t½ ~56 min; 400 U/kg yields ~152 min). At lower doses (e.g., 25 U/kg), t½ is ~30 min. Prolonged in hepatic or renal impairment.
12–17 hours (terminal); prolonged to 18–35 hours in severe renal impairment (CrCl <30 mL/min); supports twice-daily dosing
Primarily renal; metabolism by hepatic and reticuloendothelial system desulfation yields uroheparin, which is excreted in urine. Unchanged heparin is also excreted renally, with elimination proportional to dose and molecular weight. Biliary/fecal excretion is negligible (<5%).
Renal (80% unchanged); fecal/biliary (20% as inactive metabolites via P-glycoprotein-mediated secretion)
Category A/B
Category C
Anticoagulant
Anticoagulant